SGHT
HealthcareSight Sciences, Inc.
$7.71
+$0.23 (+3.07%)
Jan 5, 2026
Price History (1Y)
Analysis
Sight Sciences, Inc. is a healthcare company operating in the medical devices industry. The company has a market capitalization of $407.64 million and generates revenue of approximately $76.05 million on a trailing 12-month basis. It employs around 216 individuals. The company's financial health is characterized by significant losses, with net income totaling -$46.11 million over the past year. Sight Sciences also reports negative EBITDA and free cash flow, indicating operational challenges. However, its balance sheet shows a manageable debt level of $40.69 million against a cash position of $92.37 million. The company's gross margin stands at 86.0%, while operating and profit margins are significantly lower at -25.6% and -60.6%, respectively. Sight Sciences' valuation is reflected in its forward price-to-earnings ratio, which is -12.89. The company's revenue growth rate over the past year is -1.2%. Additionally, the debt-to-equity ratio stands at 63.28, indicating a substantial level of leverage.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Sight Sciences, Inc.
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases. The company operates in two segments, Surgical Glaucoma and Dry Eye. Its products include OMNI surgical system, an implant-free, handheld, single-use, therapeutic technology that enables ophthalmic surgeons to perform a comprehensive procedure indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, as well as for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and SION surgical instrument, a bladeless manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The company also provides TearCare system, a dry eye device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Visit website →Key Statistics
- Market Cap
- $407.64M
- P/E Ratio
- N/A
- 52-Week High
- $9.24
- 52-Week Low
- $2.03
- Avg Volume
- 254.46K
- Beta
- 2.41
Company Info
- Industry
- Medical Devices
- Exchange
- NMS
- Country
- United States
- Employees
- 216